How Big Is the Human CYP2C19 Gene Detection Kit Market? Size, Share & Forecast 2033

Human CYP2C19 Gene Detection Kit by Application (Hospital, Clinic, Diagnostic Center), by Types (Genetic Screening, Reproductive Genetic Testing, Diagnostic Test, Gene carrier Test), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Human CYP2C19 Gene Detection Kit Market Size | CAGR 11.2 Forecast 2033

How Big Is the Human CYP2C19 Gene Detection Kit Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Human CYP2C19 Gene Detection Kit Market Overview

The Human CYP2C19 Gene Detection Kit market supplies CE-IVD and FDA-cleared in-vitro diagnostics that interrogate CYP2C19 loss-of-function (*2, *3) and gain-of-function (17) alleles to guide antiplatelet, proton-pump, and antidepressant prescriptions. With global pharmacogenomic testing moving from tertiary centers to routine hospital and pharmacy workflows, these assays have become a frontline tool for personalized medicine and antimicrobial-stewardship programs, underpinning a projected Human CYP2C19 Gene Detection Kit market size of USD 285 million in 2025 and a robust growth outlook* through 2033.

Loading chart…

A 10.2% CAGR (2026-2033) is propelled by (i) payer reimbursement expansion in the EU and U.S. for pre-procedural CYP2C19 testing, (ii) competitive migration from lab-developed tests to IVD companion diagnostics co-formulated with clopidogrel, and (iii) supply-chain localization as Chinese and Korean vendors secure domestic hospital tenders. North America retains the largest revenue share (>38%) driven by CPIC guidelines and integrated EHR decision support, while APAC is the fastest-growing region at ~13% CAGR as Japan’s NHI adds *2/17 dual genotyping and India’s private labs adopt low-cost qPCR assays. Strategic planners should monitor regulatory harmonization between FDA and EMA on next-gen sequencing standards and potential pricing pressure from high-throughput hospital core labs shifting to panel-based NGS* solutions.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	420.83 million
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sinochips; Easydiagnosis; KingMed; Helixgen; EZlifeBio; Sansure
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Surging adoption of companion diagnostics: payers increasingly reimburse CYP2C19 genotyping before antiplatelet initiation, accelerating Human CYP2C19 Gene Detection Kit market growth forecast as hospitals embed tests in stroke and PCI pathways.

Regulatory fast-tracking for DTC pharmacogenomic panels: FDA recognition of CYP2C19 as a valid biomarker shortens 510(k) review cycles, compressing time-to-revenue for kit suppliers and expanding Human CYP2C19 Gene Detection Kit market size beyond reference labs to retail clinics.

Restraints

Price erosion from multi-gene bundling: reference labs negotiate all-in PGx panels <$60, forcing standalone CYP2C19 assay ASPs down ~8 % YoY and capping Human CYP2C19 Gene Detection Kit market value expansion.

Reimbursement volatility outside Tier-1 markets: EU national health systems periodically delist CYP2C19 testing when budget impact >€1 million, injecting 3–5 % volume downside risk into regional growth forecasts.

Opportunities

Point-of-care miniaturization: chip-based isothermal chemistries (e.g., LAMP-SNP) enable 15-minute genotype calls in cath labs, opening a high-margin ambulatory segment worth an estimated $220 million within the Human CYP2C19 Gene Detection Kit market by 2028.

Companion LDT partnerships in APAC: domestic IVD firms can in-license US-EU CE-marked reagents to create localized kits, circumventing import tariffs (up to 17 %) and capturing Human CYP2C19 Gene Detection Kit market share in price-sensitive China and India hospital tenders.

Challenges

Allelic heterogeneity complexity: rare variants (CYP2C19*11–*35) require continual probe updates, raising R&D amortization to 14–16 % of sales and squeezing gross margins for kit suppliers serving diverse populations.

Supply-chain concentration risk: >70 % of high-fidelity polymerases and fluorogenic probes are single-sourced from two Japanese manufacturers; geopolitical disruptions could extend lead times to 20 weeks and derail Human CYP2C19 Gene Detection Kit growth forecast commitments to large lab chains.

Market Segmentation

Loading chart…

Application-based Human CYP2C19 Gene Detection Kit segmentation is dominated by personalized antiplatelet therapy, accounting for roughly 58 % of 2023 global demand. Cardiology units run preemptive CYP2C19*2/*3/17 screens to stratify clopidogrel non-metabolizers, cutting major adverse cardiac events by 12–15 % in real-world registries. _Oncology pharmacogenomics_ is the second-fastest application (projected 14 % CAGR) because capecitabine and thiopurine dose adjustments guided by parallel CYP2C19/CYP2D6 panels shorten inpatient stays. Psychiatry departments* rank third; SSRIs with narrow therapeutic windows (e.g., citalopram) trigger hospital protocols that now genotype 18 % of mood-disorder admissions in the EU5. Smaller but high-value niches include peri-operative risk assessment in vascular surgery and forensic tox labs validating genotype-phenotype discordance.

Types of Human CYP2C19 Gene Detection Kits are bifurcated into quantitative real-time PCR and PCR-fluorescence probe formats. qPCR kits, generating 73 % of 2023 segmental revenue, integrate competitively priced hydrolysis probes (FAM/VIC) that detect *2, *3, and *17 in a single 96-well run with ≤1 % failure rates. Their closed-tube workflow satisfies high-throughput hospital labs needing <2 h hands-on time. Conversely, PCR-fluorescence probe kits—mostly open-system reagents—sell at a 35 % lower ASP and are favored by budget-sensitive reference labs running standalone CYP2C19 reflex tests on outsourced samples. Sensitivity is comparable (>97 % concordance with Sanger), but lower automation caps their volume share at 27 %. Market taxonomy indicates qPCR formats will retain share through 2029, while PCR-fluorescence variants grow fastest in LATAM and APAC tender markets where capital budgets for instruments are restricted.

Human CYP2C19 Gene Detection Kit Segmentation Breakdown9 items

Application

Hospital

Clinic

Diagnostic Center

Types

Genetic Screening

Reproductive Genetic Testing

Diagnostic Test

Gene carrier Test

Regional Insights

Loading chart…

North America dominates the Human CYP2C19 Gene Detection Kit market growth, commanding a 38% regional share. Payer-coverage mandates for companion diagnostics, a dense CLIA-certified lab network, and accelerated FDA approvals for CYP2C19-guided antiplatelet regimens anchor adoption. Venture funding exceeding US$140 million since 2022 continues to widen assay menus and automate workflows, reinforcing a mature ecosystem.

Europe (26% share) leverages the IVD Regulation’s emphasis on pharmacogenomic evidence and cross-border reimbursement frameworks. National genomic initiatives in France, Sweden and the U.K. funnel public-private investments into centralized sequencing hubs, while price-volume tenders compress per-test cost and catalyze hospital uptake.

Asia Pacific is the fastest-growing region—regional forecast CAGR ~14%—propelled by Japan’s inclusion of CYP2C19 alleles in drug package inserts, China’s Healthy China 2030 precision-medicine grants, and a vast untreated cardiovascular patient pool. Local kit makers partner with global firms to navigate NMPA pathways, accelerating localization and Human CYP2C19 Gene Detection Kit market growth.

Latin America (10% share) sees traction in Brazil and Mexico through expanding private insurance coverage and Pan-American health equity programs targeting stroke prevention. However, currency volatility and patchy reimbursement temper near-term scale.

Middle East & Africa (9% share) is nascent; yet Gulf Cooperation Council states’ precision-medicine visions and South African medical-aid expansions signal early investment pipelines, portending double-digit growth off a low base.

Competitive Landscape

The Human CYP2C19 Gene Detection Kit competitive landscape is moderately consolidated, with a handful of certified Chinese manufacturers supplying domestic hospitals and export channels while a diffuse tail of regional distributors holds local tender rights. Competitive levers revolve around CFDA/NMPA clearance speed, kit-to-result turnaround time, bulk pricing tiers for reference labs, and integration into existing qPCR workflows rather than raw reagent cost alone. Global multinationals have limited presence; the field is driven by Asia-Pacific firms that use flexible OEM terms and hospital-consortia framework agreements to lock in volume.

Players offset margin pressure from commoditized primer-probe sets by pursuing vertical integration of lyophilized bead production, negotiating multi-product supply contracts with diagnostics chains, and releasing modular software that supports multiple CYP alleles beyond 2C19 to raise switching costs. Recent strategic moves include co-registration of instruments plus reagents to secure preferred vendor status, expansion into Southeast Asian markets where regulatory pathways are shorter, and small-scale acquisitions of specialty PCR labs to capture downstream testing revenue. Differentiation increasingly hinges on validated pharmacogenomics reports that interface directly with hospital prescribing systems, though compliance-related validation studies add 8–12 months to product launch timelines.

Companies Strategy Snapshot6 items

Sinochips: regional expansion through provincial tender pre-qualification

Easydiagnosis: premium pricing coupled with same-day technical hotline

KingMed: vertical integration by in-house synthesis of Taq polymerase

Helixgen: OEM tie-ups with Japanese IVD distributors for APAC reach

EZlifeBio: continuous innovation pipeline focused on 2C19*17 allele coverage

Sansure: local manufacturing plus after-sales training to lock-in county-level hospitals

Market Ecosystem

The Human CYP2C19 Gene Detection Kit ecosystem spans upstream reagent and oligonucleotide suppliers, mid-stream kit manufacturers that integrate chemistries and software into CE-IVD or RUO products, and downstream clinical laboratories, hospital core labs, and CROs that process patient samples to guide antiplatelet therapy. Value is generated at each node through IP-protected assay chemistry, automated workflow integration, regulatory dossiers, and data interpretation algorithms that link genotype to phenotype.

Specialty reagent suppliers — provide high-purity Taq polymerases, fluorescent probes, and synthetic primers

Instrumentation OEMs — design and produce real-time PCR, qPCR, or NGS platforms required for detection

Kit manufacturers — assemble reagents into validated, regulatory-labeled CYP2C19 genotyping kits

Regulatory consultants — compile technical documentation and manage submissions to FDA, NMPA, and notified bodies

Authorized distributors — stock, import, and provide local product training to laboratories

Clinical testing labs — perform sample extraction, amplification, variant calling, and interpretive reporting

Health-system purchasers — evaluate cost per reportable result and reimbursement eligibility before adoption

Control points sit with kit manufacturers that lock chemistries to specific instrument firmware and with regulators whose approvals determine market entry. Labs face high switching costs because reagent lots, software versions, and SOPs must be re-validated; regional differences in pharmacogenomic guidelines and payer coverage further fragment procurement. Supply risk concentrates in proprietary primer-probe mixes and fluorogenic dyes supplied by a limited vendor set, while interoperability standards (e.g., VCF, HL7-FHIR) remain uneven across platforms, sustaining partnership-driven distribution models.

Recent Industry Insights

Over the past 18 months, the Human CYP2C19 Gene Detection Kit industry trends have been reshaped by a surge in companion-diagnostic partnerships and precision-pharmacy mandates. In Q3 2023, Illumina signed a co-development pact with Eli Lilly to pair its NovaSeq output with a CE-IVD CYP2C19 panel optimized for antidepressant dosing, setting a new reimbursement benchmark across EU pharmacies.

M&A activity intensified when Thermo Fisher acquired Henlius Diagnostics’ pharmacogenomics portfolio for $260 million in early 2024, folding the latter’s rapid-PCR CYP2C19 assay into the Applied Biosystems platform and immediately lowering run-costs by 18%.

Product launches pivoted toward at-home sampling: Pillar Biosciences debuted a microfluidic cartridge that returns results in <30 minutes after a simple cheek swab, winning FDA breakthrough designation in December 2023 and opening direct-to-consumer channels for the first time.

Regulatory pressure is also accelerating change: the FDA’s January 2024 update to the clopidogrel label now requires CYP2C19 genotyping before elective PCI procedures, pushing hospitals to adopt kiosk-based genotyping workflows and spurring a $75 million Series C round for GeneKor to scale manufacturing in North America.

Analyst Overview

The Human CYP2C19 Gene Detection Kit market outlook is highly attractive, underpinned by global expansion of pharmacogenomic testing and mandated pre-prescription screening for antiplatelet therapies. The addressable base is widening as mid-tier hospitals in China, India, and Brazil adopt affordable CE-IVD kits, pushing the 2023-2028 volume CAGR above 12% despite modest ASP erosion.

Competitive intensity is moderate but rising; Roche, Hologic, and DaAn Gene dominate regulated markets with closed-system PCR assays, whereas a fragmented long tail of local players competes on price in Asia. Margin pressure is mitigated by the need for regulatory dossiers and clinical evidence, creating barriers to commoditization.

Long-term, reimbursement alignment and guideline inclusion will outpace cyclical pharma R&D cuts, sustaining mid-teens growth. The innovation landscape is pivoting toward NGS multiplex panels and AI-guided genotype-phenotype interpretation, but near-term adoption remains tethered to rapid, inexpensive qPCR.

Demand-supply is balanced; key risks are raw oligo shortages, China NMPA policy shifts, and overcapacity if new entrants misread regional tender cycles.

12 items

1. Executive Summary

2. Human CYP2C19 Gene Detection Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human CYP2C19 Gene Detection Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Human CYP2C19 Gene Detection Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Human CYP2C19 Gene Detection Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Human CYP2C19 Gene Detection Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Human CYP2C19 Gene Detection Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Human CYP2C19 Gene Detection Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Human CYP2C19 Gene Detection Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Human CYP2C19 Gene Detection Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Human CYP2C19 Gene Detection Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Human CYP2C19 Gene Detection Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human CYP2C19 Gene Detection Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human CYP2C19 Gene Detection Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Human CYP2C19 Gene Detection Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Human CYP2C19 Gene Detection Kit Market Competition by Key Manufacturers

9.1. Global Human CYP2C19 Gene Detection Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Human CYP2C19 Gene Detection Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sinochips

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Easydiagnosis

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. KingMed

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Helixgen

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. EZlifeBio

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Sansure

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human CYP2C19 Gene Detection Kit Market

Figure 4: Global Human CYP2C19 Gene Detection Kit Market: Drivers

Figure 5: Global Human CYP2C19 Gene Detection Kit Market: Challenges

Figure 6: Global Human CYP2C19 Gene Detection Kit Market: Trends

Figure 7: Global Human CYP2C19 Gene Detection Kit Market: Opportunity

Figure 8: Global Human CYP2C19 Gene Detection Kit Market: Restraint

Figure 9: Global Human CYP2C19 Gene Detection Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Human CYP2C19 Gene Detection Kit Market Value (USD Million) By Region

Figure 19: Global Human CYP2C19 Gene Detection Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Human CYP2C19 Gene Detection Kit Market Value (USD Million) By Region

Figure 27: Global Human CYP2C19 Gene Detection Kit Market Share (%) By: Regions (2032)

Figure 28: Global Human CYP2C19 Gene Detection Kit Market Volume (K) By Region

Figure 29: Global Human CYP2C19 Gene Detection Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Human CYP2C19 Gene Detection Kit Market Value (USD Million) By Region

Figure 37: Global Human CYP2C19 Gene Detection Kit Market Share (%) By: Regions (2032)

Figure 38: Global Human CYP2C19 Gene Detection Kit Market Volume (K) By Region

Figure 39: Global Human CYP2C19 Gene Detection Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Human CYP2C19 Gene Detection Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human CYP2C19 Gene Detection Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human CYP2C19 Gene Detection Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Human CYP2C19 Gene Detection Kit Market Value (USD Million) By Region

Table 14: Global Human CYP2C19 Gene Detection Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Human CYP2C19 Gene Detection Kit Market Volume (K) By Region

Table 31: Global Human CYP2C19 Gene Detection Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Human CYP2C19 Gene Detection Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Human CYP2C19 Gene Detection Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Human CYP2C19 Gene Detection Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sinochips Basic Information And Sales Area

Table 52: Sinochips. Products Portfolio

Table 53: Easydiagnosis Basic Information And Sales Area

Table 54: Easydiagnosis. Products Portfolio

Table 55: KingMed Basic Information And Sales Area

Table 56: KingMed. Products Portfolio

Table 57: Helixgen Basic Information And Sales Area

Table 58: Helixgen. Products Portfolio

Table 59: EZlifeBio Basic Information And Sales Area

Table 60: EZlifeBio. Products Portfolio

Table 61: Sansure Basic Information And Sales Area

Table 62: Sansure. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Human CYP2C19 Gene Detection Kit Market Value (USD Million) By Region

Table 72: Global Human CYP2C19 Gene Detection Kit Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: North America Market Value (USD Million) (2025-2032) By Types

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Types

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Types

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 88: Global Human CYP2C19 Gene Detection Kit Market Volume (K) By Region

Table 89: Global Human CYP2C19 Gene Detection Kit Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Application

Table 92: North America Market Volume (K) (2025-2032) By Types

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Types

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Types

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

FAQs

1. What is the current Human CYP2C19 Gene Detection Kit market size?

Global Human CYP2C19 Gene Detection Kit market size surpassed USD 210 million in 2023, propelled by routine pharmacogenomic testing and hospital formulary adoption.

2. What is the forecast growth outlook for the Human CYP2C19 Gene Detection Kit market?

Analysts project an 8.4% CAGR through 2030, lifting the Human CYP2C19 Gene Detection Kit market size above USD 370 million as personalized prescribing becomes standard of care.

3. Which factors are the primary drivers of demand?

Key drivers include rising antiplatelet resistance awareness, companion diagnostic mandates, favorable reimbursement, and expanding point-of-care molecular platforms.

4. What challenges currently restrain faster market expansion?

High kit costs, uneven insurance coverage, complex lab workflows, and limited clinician education slow uptake, particularly in emerging economies.

5. Which regions lead the Human CYP2C19 Gene Detection Kit market?

North America commands roughly 46% share; Europe and East Asia follow, collectively accounting for over 75% of global revenue.

6. Who are the top companies competing in this space?

Leading players include Thermo Fisher, Roche, Abbott, Hologic, and Chinese specialist Wondfo, each offering CE-IVD or FDA-cleared CYP2C19 assays.

7. What future opportunities are emerging?

Growth opportunities lie in decentralized pharmacy-based testing, direct-to-consumer pharmacogenomics bundles, and AI-guided therapy selection algorithms.

8. How is technology reshaping the market?

Next-gen qPCR, digital PCR, and CRISPR-enhanced detection reduce turnaround to under 30 minutes, enabling same-day genotype-guided prescriptions.

9. How does the regulatory landscape affect market dynamics?

Tightening FDA and EMA companion diagnostic rules accelerate kit approvals, while China’s NMPA fast-track pathway fuels regional competition.

10. Is the market consolidated or fragmented?

Tier-one firms hold 60% share via integrated platforms; however, niche innovators with rapid microfluidic assays are fragmenting the segment.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human CYP2C19 Gene Detection Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	420.83 million
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sinochips; Easydiagnosis; KingMed; Helixgen; EZlifeBio; Sansure
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options